INVESTORS

Press Releases

Year

Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells

October 8, 2021

Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

September 27, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso , newly...

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

September 27, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the...

Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 10, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C....

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

September 9, 2021

iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision’s...

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

September 9, 2021

- Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 - Announced Licensing and...

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

September 2, 2021

Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. , NEW YORK & LONDON --(BUSINESS WIRE)--Sep. 2, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company...

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

August 25, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Aug. 25, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will host its first R&D event focused...

Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 12, 2021

- Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete Response Rate of 50% at Day ≥ 28 - Dosed First Patient in CD19-Targeted Phase 1 Clinical Trial with PBCAR19B Immune-Evading Stealth Cell - Precision to Host First In Vivo Gene...

Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

August 5, 2021

DURHAM, N.C. --(BUSINESS WIRE)--Aug. 5, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will publish financial results for the...

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 37

Investors

Corporate Governance
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Deck
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies